New hope for transplant hearts: study tests safer Anti-Rejection drug
NCT ID NCT06291077
Summary
This study aims to see if a newer anti-rejection drug called belatacept is better for heart and blood vessel health than standard drugs in kidney transplant patients. It will involve 44 people who have had a kidney transplant for over a year. Researchers will measure blood vessel function over six months to see which drug helps more.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.